Physician profile
Ritu Kapoor
NPI 1417373820
$5,568.98
in general payments reported to CMS, 2019-2025
47 companies · $893 in 2025
The $893 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,713 · 2022: $1,054 · 2023: $462 · 2024: $1,446 · 2025: $893.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,793 · Education: $8.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,792.64 |
| Education | $8.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,030.86 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $880.65 | 2021-2025 | |
| Lilly USA, LLC | $468.31 | 2021-2025 | Zepbound, Jardiance, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $400.33 | 2022-2025 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $357.94 | 2021-2025 | Trelegy Ellipta |
| Pfizer INC. | $273.96 | 2021-2024 | |
| Amgen INC. | $256.83 | 2021-2025 | Repatha, Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $169.70 | 2021-2025 | Xifaxan |
| Paratek Pharmaceuticals, INC. | $159.37 | 2021-2025 | Nuzyra, Xhance |
| Horizon Therapeutics Plc | $123.64 | 2021 | |
| Amarin Pharma, INC. | $113.53 | 2021-2022 | |
| Esperion Therapeutics, INC. | $108.17 | 2021-2025 | Nexletol |
| Abbott Laboratories | $99.90 | 2021-2022 | |
| Astellas Pharma US INC | $86.11 | 2022-2025 | Veozah |
| Shield Therapeutics INC | $71.94 | 2023-2025 | Accrufer |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ritu Kapoor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.